Metastasis-Directed Therapy Versus Systemic Therapy in Oligometastatic Endometrial Carcinoma Recurrence: A Population-Based Registry Analysis
- 1Department of Obstetrics and Gynecology, Otto von Guericke University Magdeburg, 39120 Magdeburg, Germany
Abstract
Background/Objectives: Comparative data on metastasis-directed therapy (MDT) versus systemic therapy in oligometastatic endometrial carcinoma (EC) recurrence are lacking. Methods: In this retrospective population-based registry study (Tumor Register Saxony-Anhalt, 2000–2025), we included 153 treated patients with distant-only oligometastatic EC recurrence (≤2 anatomical sites) after curative-intent primary treatment. Overall survival (OS) was compared between a strategy including MDT (n = 97) and systemic therapy alone (n = 56) using inverse probability of treatment weighting (IPTW)-adjusted Cox regression. Subgroup, sensitivity and competing risks analyses were exploratory. Results: In the IPTW analysis (n = 145 with complete data), OS did not differ significantly between MDT and systemic therapy (hazard ratio [HR] 0.90, 95% confidence interval [CI] 0.61–1.35; p = 0.622), consistent across sensitivity analyses. In exploratory subgroup analysis, MDT was associated with better OS in high-grade tumors (n = 51; HR 0.27, 95% CI 0.12–0.59; p = 0.001; Holm-adjusted p = 0.013), but not in low-grade tumors (HR 1.29; p = 0.339). Conclusions: MDT and systemic therapy showed no statistically significant survival difference in unselected oligometastatic EC recurrence; the confidence interval cannot exclude clinically relevant benefit or harm, supporting individualized decisions. The high-grade finding is hypothesis-generating and warrants prospective validation.
Related
- Integrating Systemic Inflammation, Nutrition and Skeletal Muscle into a Composite Score (the HALP–Sarcopenia Combined Index) for Preoperative Risk Stratification of Lymph-Node Metastasis and Recurrence in Endometrial Carcinoma: A Single-Centre Retrospective Study
- Late Recurrence of Gastric Signet-Ring Cell Carcinoma Presenting as Pulmonary Metastasis 18 Years after Gastrectomy: A Case Report and Literature Review
- Case Report: Rapid recurrence and nodal metastasis of laryngeal spindle cell squamous cell carcinoma initially underestimated on superficial sampling
- Addition of Metastasis-Directed Therapy to Standard of Care for Oligometastatic Disease: Primary Aggregated Analysis of All Baskets from the Phase II Randomized EXTEND Trial
- Intramedullary Spinal Cord Metastasis From Oligometastatic Melanoma of Unknown Primary Treated With Stereotactic Body Radiotherapy.
BibTeX
@article{gennari2026metastasisdirected,
title = {{Metastasis-Directed Therapy Versus Systemic Therapy in Oligometastatic Endometrial Carcinoma Recurrence: A Population-Based Registry Analysis}},
author = {Paolo Gennari and Mandy Busse and Atanas Ignatov},
journal = {Cancers},
year = {2026},
month = oct,
doi = {10.3390/cancers18203382},
url = {https://www.mdpi.com/2072-6694/18/20/3382},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Metastasis-Directed Therapy Versus Systemic Therapy in Oligometastatic Endometrial Carcinoma Recurrence: A Population-Based Registry Analysis
AU - Paolo Gennari
AU - Mandy Busse
AU - Atanas Ignatov
PY - 2026
DA - 2026/10/19
JO - Cancers
DO - 10.3390/cancers18203382
UR - https://www.mdpi.com/2072-6694/18/20/3382
AB - Background/Objectives: Comparative data on metastasis-directed therapy (MDT) versus systemic therapy in oligometastatic endometrial carcinoma (EC) recurrence are lacking. Methods: In this retrospective population-based registry study (Tumor Register Saxony-Anhalt, 2000–2025), we included 153 treated patients with distant-only oligometastatic EC recurrence (≤2 anatomical sites) after curative-intent primary treatment. Overall survival (OS) was compared between a strategy including MDT (n = 97) and systemic therapy alone (n = 56) using inverse probability of treatment weighting (IPTW)-adjusted Cox regression. Subgroup, sensitivity and competing risks analyses were exploratory. Results: In the IPTW analysis (n = 145 with complete data), OS did not differ significantly between MDT and systemic therapy (hazard ratio [HR] 0.90, 95% confidence interval [CI] 0.61–1.35; p = 0.622), consistent across sensitivity analyses. In exploratory subgroup analysis, MDT was associated with better OS in high-grade tumors (n = 51; HR 0.27, 95% CI 0.12–0.59; p = 0.001; Holm-adjusted p = 0.013), but not in low-grade tumors (HR 1.29; p = 0.339). Conclusions: MDT and systemic therapy showed no statistically significant survival difference in unselected oligometastatic EC recurrence; the confidence interval cannot exclude clinically relevant benefit or harm, supporting individualized decisions. The high-grade finding is hypothesis-generating and warrants prospective validation.
SN - 2072-6694
ER -